GlassScriptPhysician profile
Nicole Mccommon
NPI 1750592440
$2,346.60
in general payments reported to CMS, 2019-2025
30 companies · $953 in 2025
The $953 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $286 · 2021: $345 · 2022: $169 · 2023: $114 · 2024: $213 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.42 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $328.45 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $313.98 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $299.51 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $183.68 | 2019-2024 | Trelegy Ellipta |
| Pfizer INC. | $92.89 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.07 | 2024-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.56 | 2021-2024 | Jardiance, Synjardy |
| Axsome Therapeutics, INC. | $58.48 | 2025 | Auvelity |
| Alkermes, INC. | $56.62 | 2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.14 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $42.23 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $40.60 | 2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $37.28 | 2024 | |
| Phathom Pharmaceuticals, INC. | $33.93 | 2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $33.16 | 2025 | Cobenfy |
| Abbott Laboratories | $24.06 | 2024 | Cell-Dyn |
| Bayer Healthcare Pharmaceuticals INC. | $23.96 | 2022 | |
| Gilead Sciences, INC. | $21.24 | 2023 | |
| Insulet Corporation | $19.02 | 2025 | Omnipod |
| Exact Sciences Corporation | $18.90 | 2025 | The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $18.33 | 2023 | Yupelri |
| Arbor Pharmaceuticals, INC. | $17.83 | 2020 | |
| Ardelyx, INC. | $17.24 | 2024 | Ibsrela |
| Boston Scientific Corporation | $16.03 | 2023 | Watchman Flx |
| Cumberland Pharmaceuticals, INC. | $15.11 | 2023 | Kristalose |
| Xeris Pharmaceuticals, INC. | $13.75 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.03 | 2020 | |
| Inogen, INC. | $8.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Mccommon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.